 Back to Annual Meeting
|
|
Back to Annual Meeting
|
APHA Scientific Session and Event Listing |
Abstract #153980
Audio (mp3) recordingAbby Rudolph, BA, Katherine Standish, BA, Kellee White, Ebele O. Benjamin, MPH, David Vlahov, PhD, and Crystal M. Fuller, PhD. Center for Urban Epidemiologic Studies, New York Academy of Medicine, 1216 Fifth Avenue, New York, NY 10029, 212-822-7274, arudolph@nyam.org
Background: The expanded syringe access demonstration program (ESAP), enacted in August 2000 and implemented in January 2001 to reduce infectious disease transmission among injection drug users (IDUs), allows healthcare providers to distribute and pharmacies to sell non-prescription needles/syringes (referred to as “syringes” hereafter) in New York State. Many IDUs lack health insurance and/or fear being mistreated in the healthcare system because of their drug use. ESAP-participating pharmacists may be positioned to provide discrete and confidential health information to syringe customers and help link IDUs with addiction-specialized providers and other medical/social services. Objective: Determine if there is a relationship between frequency of pharmacy syringe purchase visits and access to drug treatment and/or medical care among IDUs in New York City. Methods: Cross-sectional analysis of data collected from participants recruited using street-intercept sampling in 36 socioeconomically disadvantaged, ethnographically-defined neighborhoods in four New York City boroughs was conducted (2005-2007). Interviewer-administered questionnaires collected information on demographics, injection practices, frequency of pharmacy-purchased syringes, access to services, and drug use cessation attempts. Analysis was restricted to self-reported IDUs. Separate logistic regression models predicting frequent pharmacy-use vs. non-pharmacy use and infrequent pharmacy-use vs. non-pharmacy use were created. Results: Of the 218 IDUs enrolled, the median age was 36 (18-58 range), 67% were Hispanic, 18% Black, 72% male, 37% infrequent pharmacy-users and 17% frequent pharmacy-users. After controlling for participation in other syringe access programs, frequent pharmacy-users were significantly more likely to have doctors and share cotton, and less likely to inject frequently, share rinse-water, use shooting galleries, borrow syringes, enter drug treatment or stop injecting, and have heroin dependence than never-pharmacy users. Infrequent pharmacy-users were significantly more likely to share cotton and less likely to inject frequently, lend syringes, enter drug treatment or stop injecting, and have crack or heroin dependence than never-pharmacy users. After adjusting for injection behaviors, infrequent pharmacy-users were older (AOR=3.53), and less likely to stop injecting (AOR=0.36) or enter drug treatment (AOR=0.28). Frequent pharmacy-users were older (AOR=3.95), more likely to have doctors (AOR=3.59), and less likely to enter drug treatment (AOR=0.20). Conclusions: These data suggest that IDUs who use pharmacies frequently tend to have some type of healthcare access. Therefore, an expanded public health role for pharmacies including consultation on medical care, safe injection practices, and drug treatment should be explored. IDUs have the potential to benefit greatly from public health-minded pharmacists and public health efforts to increase pharmacy syringe access should be pursued.
Learning Objectives:
- Recognize that a lack of health insurance combined with apprehension about seeking medical care contribute to the poor health of injection drug users.
- Discuss the potential for pharmacies to intervene and improve access to medical and social services for injection drug users who purchase syringes at pharmacies.
- Take steps to improve nonprescription syringe access via pharmacies and create a stronger public health role for pharmacies and their staff.
Keywords: Health Care Access, Pharmacies
Presenting author's disclosure statement:
Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
The 135th APHA Annual Meeting & Exposition (November 3-7, 2007) of APHA